Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Variants in ACTC1 underlie distal arthrogryposis accompanied by congenital heart defects.
Chong JX, Childers MC, Marvin CT, Marcello AJ, Gonorazky H, Hazrati LN, Dowling JJ, Al Amrani F, Alanay Y, Nieto Y, Gabriel MÁM, Aylsworth AS, Buckingham KJ, Shively KM, Sommers O, Anderson K; University of Washington Center for Mendelian Genomics; University of Washington Center for Rare Disease Research; Regnier M, Bamshad MJ. Chong JX, et al. Among authors: nieto y. HGG Adv. 2023 Jun 15;4(3):100213. doi: 10.1016/j.xhgg.2023.100213. eCollection 2023 Jul 13. HGG Adv. 2023. PMID: 37457373 Free PMC article.
Enhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.
Nieto Y, Ramdial J, Valdez B, Thall PF, Bassett R, Barnett M, Srour S, Hosing C, Alousi A, Qazilbash M, Popat U, Gulbis A, Shigle TL, Ahmed S, Guillermo Pacheco M, Champlin R, Shpall EJ, Andersson BS. Nieto Y, et al. Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-3544. Online ahead of print. Clin Cancer Res. 2025. PMID: 39804167
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation.
Pasvolsky O, Marcoux C, Wang Z, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee HC, Patel KK, Becnel MR, Ye C, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Pasvolsky O, et al. Among authors: nieto y. Transplant Cell Ther. 2024 Dec 31:S2666-6367(24)00841-8. doi: 10.1016/j.jtct.2024.12.023. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39746546
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O. Marcoux C, et al. Among authors: nieto y. Br J Haematol. 2024 Nov 28. doi: 10.1111/bjh.19937. Online ahead of print. Br J Haematol. 2024. PMID: 39610225 No abstract available.
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: nieto y. Blood Cancer J. 2024 Oct 31;14(1):189. doi: 10.1038/s41408-024-01165-w. Blood Cancer J. 2024. PMID: 39482325 Free PMC article.
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p.
Marcoux C, Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Ahmed A, Aljawai Y, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Marcoux C, et al. Among authors: nieto y. Transplant Cell Ther. 2025 Jan;31(1):12.e1-12.e10. doi: 10.1016/j.jtct.2024.10.011. Epub 2024 Oct 22. Transplant Cell Ther. 2025. PMID: 39448031
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. Ramdial J, et al. Among authors: nieto y. Bone Marrow Transplant. 2024 Dec;59(12):1754-1762. doi: 10.1038/s41409-024-02394-0. Epub 2024 Sep 28. Bone Marrow Transplant. 2024. PMID: 39341929 Free PMC article.
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades.
Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: nieto y. Transplant Cell Ther. 2024 Aug;30(8):772.e1-772.e11. doi: 10.1016/j.jtct.2024.06.001. Epub 2024 Jun 7. Transplant Cell Ther. 2024. PMID: 38852784
305 results